Étiquette : LSD

Marginalisation, stigmatisation et abandon du LSD en médecine, Zoë Dubus, 2019

Marginalisation, stigmatisation et abandon du LSD en médecine Zoë Dubus Histoire, médecine et santé, 2019, 15, 87-105 Doi : 10.4000/hms.2168 https://journals.openedition.org/hms/2168 Abstracts Après avoir été l’une des substances pharmacologiques les plus étudiées des années 1950-1970, le LSD, puissant psychédélique ayant de nombreuses indications thérapeutiques, est abandonné par la communauté scientifique internationale au début des années 1970. Si des facteurs externes à la médecine ont eu un impact sur le déclin de ce médicament, il est également nécessaire de s’interroger sur les causes internes de ce rejet. Pour ce faire, une littérature anglo-saxonne émerge ces dernières années dans le champ des psychedelic studies, que nous enrichissons ici par une [...]

Lire la suite

Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing, L.S. Kaertner et al., 2021

Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing, KAERTNER L.S., STEINBORN M.B., KETTNER H., SPRIGGS M.J., ROSEMAN L., BUCHBORN T., BALAET M., TIMMERMANN C., ERRITZOE D., CARHARDT-HARRIS R.L. : Nature, 2021, 11, 1941 Doi : 1038/s41598-021-81446-7   Abstract Psychedelic microdosing describes the ingestion of near-threshold perceptible doses of classic psychedelic substances. Anecdotal reports and observational studies suggest that microdosing may promote positive mood and well-being, but recent placebo-controlled studies failed to find compelling evidence for this. The present study collected web-based mental health and related data using a prospective (before, during and after) design. Individuals planning a weekly microdosing regimen completed surveys at strategic [...]

Lire la suite

Reviewing the Potential of Psychedelics for the Treatment of PTSD, Erwin Krediet et al., 2020

Reviewing the Potential of Psychedelics for the Treatment of PTSD Erwin Krediet, Tijmen Bostoen, Joost Breeksema, Annette van Schagen, Torsten Passie, Eric Vermetten International Journal of Neuropsychopharmacology, 2020, 23, (6), 385–400 doi : 10.1093/ijnp/pyaa018 https://pubmed.ncbi.nlm.nih.gov/32170326/   Abstract There are few medications with demonstrated efficacy for the treatment of posttraumatic stress disorder (PTSD). Treatment guidelines have unequivocally designated psychotherapy as a first line treatment for PTSD. Yet, even after psychotherapy, PTSD often remains a chronic illness, with high rates of psychiatric and medical comorbidity. Meanwhile, the search for and development of drugs with new mechanisms of action has stalled. Therefore, there is an urgent need to explore not [...]

Lire la suite

Post-acute psychological effects of classical serotonergic psychedelics : a systematic review and meta-analysis, Simon B. Goldberg et al, 2020,

Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis Simon B. Goldberg, Benjamin Shechet, Christopher R. Nicholas, Chi Wing Ng, Geetanjali Deole, Zhuofan Chen and Charles L. Raison Psychological Medicine, 2020, 1–12. doi : 10.1017/S003329172000389X   Abstract Background. Scientific interest in the therapeutic effects of classical psychedelics has increased in the past two decades. The psychological effects of these substances outside the period of acute intoxication have not been fully characterized. This study aimed to: (1) quantify the effects of psilocybin, ayahuasca, and lysergic acid diethylamide (LSD) on psychological outcomes in the post-acute period; (2) test moderators of these effects; and (3) evaluate [...]

Lire la suite

Psychedelics as a Treatment for Alzheimer’s Disease Dementia, Simon Andrew Vann Jones and Allison O’Kelly, 2020

Psychedelics as a Treatment for Alzheimer’s Disease Dementia Simon Andrew Vann Jones and Allison O’Kelly Cornwall Partnership NHS Foundation Trust, Liskeard, United Kingdom Frontiers in Synaptic Neuroscience, August 2020 | Volume 12 | Article 34 doi : 10.3389/fnsyn.2020.00034   Currently, there are no disease-modifying treatments for Alzheimer’s disease (AD) or any other dementia subtype. The renaissance in psychedelic research in recent years, in particular studies involving psilocybin and lysergic acid diethylamide (LSD), coupled with anecdotal reports of cognitive benefits from micro-dosing, suggests that they may have a therapeutic role in a range of psychiatric and neurological conditions due to their potential to stimulate neurogenesis, provoke neuroplastic [...]

Lire la suite

Soignera-t-on un jour grâce au LSD et aux champignons hallucinogènes ?, Vincent Verroust et Bertrand Lebeau Leibovici, The Conversation, 8 octobre 2020

Soignera-t-on un jour grâce au LSD et aux champignons hallucinogènes ? The Conversation, 8 octobre 2020,  Mis à jour le 9 octobre 2020, https://theconversation.com/soignera-t-on-un-jour-grace-au-lsd-et-aux-champignons-hallucinogenes-127760 Auteur Vincent Verroust Chercheur associé à l’Institut des humanités en médecine (Lausanne), doctorant en histoire des sciences à l’École des hautes études en sciences sociales (Paris), centre Alexandre-Koyré (EHESS-CNRS-MNHN), Muséum national d’histoire naturelle (MNHN) Déclaration d’intérêts : Vincent Verroust est président de la Société psychédélique française.   Cet article a été co-écrit avec Bertrand Lebeau Leibovici, médecin addictologue à l’hôpital Saint-Antoine (Paris) et à l’hôpital Paul Brousse (Villejuif).   Partenaires Muséum National d’Histoire Naturelle apporte un financement en tant que membre adhérent [...]

Lire la suite

Mystical Experiences in Retrospective Reports of First Times Using a Psychedelic in Finland, Samuli Kangaslampi et al., 2020

Mystical Experiences in Retrospective Reports of First Times Using a Psychedelic in Finland Samuli Kangaslampi, PhD , Aino Hausen, BA, and Tarina Rauteenmaa, BA JOURNAL OF PSYCHOACTIVE DRUGS, 2020, 1-10 Doi : 10.1080/02791072.2020.1767321   ABSTRACT Despite their acutely inebriating and sometimes unpleasant effects, some people report positive changes in life satisfaction, well-being, or mental health after taking psychedelic drugs. One explanation may be the ability of psychedelics to trigger mystical-type experiences. We examined the validity, reliability, and factor structure of a novel Finnish translation of the Revised Mystical Experiences Questionnaire (MEQ30) among 288 people retrospectively reporting on their first time using a psychedelic. We found evidence [...]

Lire la suite

Adverse Reactions to Psychedelic Drugs. A Review of the Literature, Rick J. STRASSMAN, 1984.

Adverse Reactions to Psychedelic Drugs. A Review of the Literature Rick J. STRASSMAN, M.D. THE JOURNAL OF NERVOUS AND MENTAL DISEASE, 1984, VOL. 172, NO. 10, 577-595. DOI : 10.1097/00005053-198410000-00001   The use of naturally occurring and synthetically derived compounds for their "psychedelic" effects has been a part of human culture for thousands of years. The basic pharmacology of the major synthetic psychedelic compounds primarily lysergic acid diethylamide [LSD]-25 is described and reference is made to their potentially beneficial psychological effects. Adverse reactions, defined as dysphoric and/or maladaptive/dysfunctional responses to the use of these drugs, sometimes require careful clinical judgment in order to diagnose. These reactions [...]

Lire la suite

Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD) : a systematic review of clinical trials published in the last 25 years, Raphael G. dos Santos et al., 2016

Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD) : a systematic review of clinical trials published in the last 25 years Rafael G. dos Santos, Flávia L. Osório, José Alexandre S. Crippa, Jordi Riba, Antônio W. Zuardi and Jaime E. C. Hallak Therapeutic Advances in Psychopharmacology, 2016, Vol. 6, (3) 193–213 Doi : 10.1177/2045125316638008   Abstract : To date, pharmacological treatments for mood and anxiety disorders and for drug dependence show limited efficacy, leaving a large number of patients suffering severe and persistent symptoms. Preliminary studies in animals and humans suggest that ayahuasca, psilocybin and lysergic acid diethylamide (LSD) may have [...]

Lire la suite

Recent Advances in the Neuropsychopharmacology of Serotonergic Hallucinogens, Adam L. Halberstadt, 2015

Recent Advances in the Neuropsychopharmacology of Serotonergic Hallucinogens Adam L. Halberstadt Behavioral Brain Research, 2015, 15, 277, 99–120. doi : 10.1016/j.bbr.2014.07.016   Abstract Serotonergic hallucinogens, such as (+)-lysergic acid diethylamide, psilocybin, and mescaline, are somewhat enigmatic substances. Although these drugs are derived from multiple chemical families, they all produce remarkably similar effects in animals and humans, and they show cross-tolerance. This article reviews the evidence demonstrating the serotonin 5-HT2A receptor is the primary site of hallucinogen action. The 5-HT2A receptor is responsible for mediating the effects of hallucinogens in human subjects, as well as in animal behavioral paradigms such as drug discrimination, head twitch response, prepulse [...]

Lire la suite